The Oncologist
newsletter arrived today. Loads of interesting stuff including an article
on the treatment of lymphomas:
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
Patrizia
Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide
Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian
Follicular
lymphoma is the most common indolent lymphoma worldwide. Rituximab plus
bendamustine (R-B) has been shown to improve outcome and reduce toxicity
compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP)
in follicular lymphoma; however, in clinical practice in many centers, R-CHOP
is still the preferred treatment. This article reports the results of a study
that assessed patients with follicular lymphoma grade 3A treated with either
RCHOP or R-B in five European cancer centers.
No comments:
Post a Comment